BioSpace News Archive

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholly owned subsidiary of Kyorin Holdings, Inc.,

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

Cytovia Therapeutics, a biopharmaceutical company, and the University of California, San Francisco (UCSF) announced today that they have entered a 3-year research partnership to develop novel precision gene editing to improve the performance, safety and persistence of Natural Killer (NK) cells and Chimeric Antigen Receptor (CAR)-NK cells.

InspireMD, Inc. announced strong preliminary unaudited revenue for the fourth quarter and reported an inducement grant to the company’s new Chief Executive Officer, Marvin Slosman, who assumed the role effective January 1, 2020.

MannKind Corporation (NASDAQ: MNKD) announced today that its Brazilian partner, Biomm S.A., has received written notice from the Chamber of Regulation of the Medicines Market (CMED) approving the proposed price of Afrezza in Brazil.

Compass Therapeutics announced that Thomas Schuetz, M.D., Ph.D., co-founder and chief executive officer, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Monday, January 13, 2020.

AngioDynamics, Inc. announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Sr. Vice President, General Counsel, and Interim Chief Financial Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference at 8:00 a.m. PT on Thursday, January 16, 2020 in San Francisco, CA..

ESCAPE Bio, Inc. announced that ESB1609 demonstrated durable CSF pharmacokinetics and excellent safety & tolerability in a single ascending dose Phase 1 Study.

CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that James Xue, PhD, CANbridge Founder, Chairman and CEO, was named one of six Deputy Director Generals at the Second General Election Meeting of the Shanghai Foundation for Rare Disease, in Shanghai, China on December 21st.

Twist Bioscience Corporation announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th at 8:30 a.m. Pacific Time in San Francisco.